Summary & Overview
HCPCS J2700: Injection of Oxacillin Sodium, up to 250 mg
HCPCS Level II code J2700 denotes the injection of oxacillin sodium, up to 250 mg. This code is used to bill for parenteral administration of the beta-lactam antibiotic oxacillin in outpatient and inpatient outpatient settings. Nationally, accurate use of J2700 matters for capture of antibiotic utilization, antimicrobial stewardship tracking, and appropriate payment for infused or injected antimicrobials.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for oxacillin injections, typical sites of service, and the billing environment where J2700 is applied. The publication summarizes common modifiers and payer considerations where available, and presents benchmarks and coding guidance relevant to reimbursement and claims submission.
This briefing also outlines areas where policy updates or payer-specific requirements may affect billing for injectable antibiotics, and highlights items for operational attention such as documentation of dose, route, and administration site. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J2700 represents an injection of oxacillin sodium, up to 250 mg. This code describes a parenteral antibiotic administration where oxacillin sodium is supplied and administered in a single-dose injectable form.
-
Service type: Injectable antibiotic administration
-
Typical site of service: Ambulatory infusion clinic, hospital outpatient department, emergency department, or physician office where intravenous or intramuscular antibiotic injections are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J2700 is an adult or pediatric patient presenting to an outpatient infusion center, emergency department, or inpatient ward for parenteral treatment of a Gram-positive bacterial infection where oxacillin sodium is indicated. A common scenario is a patient with confirmed or strongly suspected methicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infection, cellulitis with systemic signs, purulent wound infection, or postoperative wound infection who requires intravenous beta-lactam therapy.
The clinical workflow: the treating clinician documents the infectious diagnosis and selects oxacillin sodium. Pharmacy prepares the ordered dose (up to 250 mg per billed unit) under sterile technique. Nursing verifies patient identity, allergy status (notably penicillin/cephalosporin allergy), and obtains baseline vital signs. The medication is administered intravenously per facility policy, observed for infusion reactions, and documented in the medical record. For outpatient or observation encounters, billing uses J2700 for each 250 mg unit supplied; infusion time, site-of-care, and any applicable modifiers are appended per payer rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier/standard |